Medofloxine (Ofloxacin)

Medofloxine (ofloxacin) is used to treat bacterial infections affecting several organ systems.

• Urinary tract infection: effective in treating uncomplicated UTIs caused by susceptible Gram‑negative bacteria.
• Respiratory tract infection: used for acute exacerbations of chronic bronchitis and community‑acquired pneumonia when caused by sensitive organisms.
• Skin and soft tissue infection: resolves cellulitis, wound infections and abscesses due to susceptible bacteria.
• Prostatitis: improves symptoms of chronic bacterial prostatitis by eradicating the causative pathogen.
• Gonorrhea: provides antimicrobial therapy for uncomplicated gonococcal infections of the urethra and cervix.

• Ofloxacin exerts its antibacterial activity by binding to bacterial DNA gyrase (topoisomerase II) and topoisomerase IV. This inhibition prevents the supercoiling and relaxation of DNA that are essential for replication and transcription, leading to bacterial cell death. The dual targeting of both enzymes broadens its spectrum against Gram‑negative and Gram‑positive organisms and reduces the likelihood of resistance development.

Like other fluoroquinolones, Medofloxine may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects

• Nausea: mild stomach upset often transient.
• Diarrhea: loose stools that may resolve without treatment.
• Headache: mild to moderate intensity.
• Dizziness: occasional sensation of light‑headedness.
• Rash: mild skin erythema or itching.

Serious or Rare Side Effects

• Tendon rupture: sudden pain and loss of function, especially in the Achilles.
• QT prolongation: cardiac rhythm disturbance that can lead to arrhythmia.
• Severe allergic reaction: anaphylaxis with swelling, breathing difficulty.
• Central nervous system effects: seizures or psychosis in susceptible individuals.
• Clostridioides difficile infection: severe colitis following intestinal flora disruption.

When prescribing Medofloxine, clinicians should consider several precautionary measures to minimise risks and ensure safe use.

• Assess renal function: dose adjustment may be required in patients with impaired clearance.
• Avoid in patients with known hypersensitivity to fluoroquinolones: discontinue immediately if reaction occurs.
• Monitor for tendon pain: advise patients to report sudden musculoskeletal discomfort.
• Caution in elderly: higher incidence of CNS effects and QT prolongation.
• Evaluate concomitant QT‑prolonging drugs: increased risk of cardiac arrhythmias.
• Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture.

Medofloxine can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Antacids containing aluminum or magnesium: reduce absorption of ofloxacin.
• NSAIDs (e.g., ibuprofen, diclofenac): increase risk of CNS stimulation and seizures.
• Warfarin: may enhance anticoagulant effect, requiring INR monitoring.

Moderate Interactions (Monitor Closely)

• Corticosteroids: heightened risk of tendon rupture.
• Cyclosporine: increased plasma levels of ofloxacin.
• QT‑prolonging agents (e.g., macrolides, fluoroquinolones): additive effect on cardiac rhythm.
• Diabetic agents (e.g., insulin, sulfonylureas): possible hypoglycaemia, monitor blood glucose.